Browsing Molecular Pathology by author "Fontana, Elisa"
Now showing items 1-8 of 8
-
A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Smyth, EC; Nyamundanda, G; Cunningham, D; Fontana, E; Ragulan, C; et al. (OXFORD UNIV PRESS, 2018-12-01)BACKGROUND: Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk ... -
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.
Ragulan, C; Eason, K; Fontana, E; Nyamundanda, G; Tarazona, N; et al. (NATURE PORTFOLIO, 2019-05-21)Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later consolidated into four consensus molecular subtypes (CMS). Here ... -
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.
Dillon, MT; Bergerhoff, KF; Pedersen, M; Whittock, H; Crespo-Rodriguez, E; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on the ... -
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study.
Cremolini, C; Benelli, M; Fontana, E; Pagani, F; Rossini, D; et al. (ELSEVIER, 2019-03-01)OBJECTIVE: Primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. Sensitivity to anti-EGFRs (Epidermal Growth Factor Receptor) of metastatic transverse colon cancers (mTCCs) has usually ... -
Class(y) Dissection of BRAF Heterogeneity: Beyond Non-V600.
Fontana, E; Valeri, N (AMER ASSOC CANCER RESEARCH, 2019-12-01)Different classes of BRAF mutations are present in colorectal and other cancers. Non-V600 mutations are rare; however, their detection rate will increase as the use of next-generation sequencing ramps up quickly in clinical ... -
Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials.
Fontana, E; Eason, K; Cervantes, A; Salazar, R; Sadanandam, A (OXFORD UNIV PRESS, 2019-04-01)The Colorectal Cancer Subtyping Consortium identified four gene expression consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), using multiple microarray or RNA-sequencing ... -
Development of biomarker assays to dissect subtype-specific heterogeneity and anti-EGFR treatment response in colorectal cancer
Sadanandam, A; Fontana, E (Institute of Cancer Research (University Of London), 2020-08-31)Colorectal cancer (CRC) is the third most frequently diagnosed type of cancer and the second leading cause of cancer deaths worldwide. Although extensive biological heterogeneity at multiple "-omics" levels has been ... -
Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study.
Khan, K; Rata, M; Cunningham, D; Koh, D-M; Tunariu, N; et al. (BMJ PUBLISHING GROUP, 2018-08-01)OBJECTIVE: Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better ...